Zurich – PharmaBiome has secured new capital in the amount of 1.75 million Swiss francs from investors. The company has also elected two new experts to its Board of Directors. PharmaBiome is developing treatments for gastrointestinal diseases.

Sherpany impresses with solution for digital meetings

 

PharmaBiome has successfully raised 1.75 million francs from new and existing investors. According to a press release, this new capital is bridge financing, with the company also planning to raise additional funds in Series A financing down the line.

The investors include Thomas Meier and Patrik Forrer. Thomas Meier, formerly the CEO of Santhera Pharmaceuticals AG, has been chosen as the new Chairman of the Board of PharmaBiome. Patrik Forrer is the other new member of the Board of Directors, having previously co-founded Molecular Partners based in Schlieren.

PharmaBiome is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH). The company is developing treatments for gastrointestinal diseases. Its lead product is PB002, a patent-protected treatment for ulcerative colitis. PB002 is a co-cultured consortium of nine bacterial strains. The raised capital will be used to initiate the first pilot clinical trial with PB002.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line. 

+41 44 254 59 59


info@greaterzuricharea.com